With the results of ODYSSEY Outcomes and the more attractive pricing for PCSK9 inhibitors, how do you now see the landscape for this therapy, especially in the context of the lipid medicine/atherosclerosis specialist and the preventive cardiologist?
With the results of ODYSSEY Outcomes and the more attractive pricing for PCSK9 inhibitors, how do you now see the landscape for this therapy, especially in the context of the lipid medicine/atherosclerosis specialist and the preventive cardiologist?
Created by
Presenter
Michael H. Davidson, MD, FACC, FACP, FNLA
Clinical Professor
Clinical Professor
Director of Preventive Cardiology
The University of Chicago Hospitals and Clinic
Pritzker School of Medicine
Chicago, Illinois